Chronic effects of repeated low-dose cisplatin treatment in mouse kidneys and renal tubular cells

Cisplatin is a commonly used chemotherapeutic drug for cancer treatment, but its nephrotoxicity may lead to the deterioration of renal function. Previous work has been focused on cisplatin-induced acute kidney disease, whereas the mechanism of chronic kidney disease after cisplatin chemotherapy is l...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of physiology. Renal physiology Vol. 317; no. 6; pp. F1582 - F1592
Main Authors Fu, Ying, Cai, Juan, Li, Fanghua, Liu, Zhiwen, Shu, Shaoqun, Wang, Ying, Liu, Yuxue, Tang, Chengyuan, Dong, Zheng
Format Journal Article
LanguageEnglish
Published United States American Physiological Society 01.12.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Cisplatin is a commonly used chemotherapeutic drug for cancer treatment, but its nephrotoxicity may lead to the deterioration of renal function. Previous work has been focused on cisplatin-induced acute kidney disease, whereas the mechanism of chronic kidney disease after cisplatin chemotherapy is largely unknown. In the present study, we have characterized the mouse model of chronic kidney defects induced by repeated low-dose cisplatin treatment. We have also established a relevant cell culture model. In the animal model, C57 mice were given weekly injection of 8 mg/kg cisplatin for 4 wk. This led to a sustained decline of kidney function. These mice showed loss of kidney mass, interstitial fibrosis, continued activation of inflammatory cytokines, and appearance of atubular glomeruli. In the cell model, the BUMPT mouse proximal tubular cell line was treated four times with 1-2 μM cisplatin, resulting in low levels of apoptosis and the expression of fibrosis proteins and profibrotic factors. These data suggest that repeated treatment with low-dose cisplatin causes long-term renal pathologies with characteristics of chronic kidney disease.
ISSN:1931-857X
1522-1466
DOI:10.1152/ajprenal.00385.2019